Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Inflamm Bowel Dis. 2018 Nov 29;24(12):2634-2640. doi: 10.1093/ibd/izy179.
Previous reports have shown differences in phenotypes among black patients with inflammatory bowel disease (IBD) compared with other racial groups, but prior studies were limited by small numbers of black patients and cross-sectional analyses. We used data from the Sinai-Helmsley Alliance for Research Excellence cohort to compare phenotypes and treatment patterns of black and white patients with IBD in a prospective study.
We compared phenotypes, IBD-specific therapies, and health care utilization among black and white patients with IBD. For all analyses, we performed bivariate analyses and multivariable logistic regression to adjust for potential confounders.
Among 5537 patients with IBD, 314 (6%) reported black race. Black patients were more likely to report a Crohn's disease (CD)-related complication at baseline (adjusted odds ratio [aOR], 1.44; 95% confidence interval [CI], 1.06-1.95). Black patients with CD were more likely to develop a new abscess (aOR, 2.27; 95% CI, 1.31-3.93) and initiate an anti-tumor necrosis factor therapy during follow-up (aOR, 1.85; 95% CI, 1.09-3.14). Black patients with ulcerative colitis were more likely to have proctitis (24% vs 13%, P = 0.033) at baseline. There were no differences in surgery or hospitalization rates during the follow-up period.
Black patients with CD demonstrated increased complications at baseline and during follow-up in this cohort. Despite more complicated disease, black and white patients with IBD were generally given the same medications and experienced similar rates of hospitalization and surgery during the study period. In our multicenter cohort, clinical outcomes among black and white patients with IBD were similar.
先前的报告显示,与其他种族群体相比,患有炎症性肠病(IBD)的黑人患者的表型存在差异,但先前的研究受到黑人患者数量少和横断面分析的限制。我们使用西奈-赫尔姆斯利联盟卓越研究队列的数据,在一项前瞻性研究中比较了 IBD 黑人患者和白人患者的表型、IBD 特异性治疗和医疗保健利用情况。
我们比较了 IBD 黑人患者和白人患者的表型、IBD 特异性治疗和医疗保健利用情况。对于所有分析,我们进行了双变量分析和多变量逻辑回归,以调整潜在的混杂因素。
在 5537 名 IBD 患者中,314 名(6%)报告为黑人。黑人患者在基线时更有可能报告克罗恩病(CD)相关并发症(调整后的优势比[OR],1.44;95%置信区间[CI],1.06-1.95)。患有 CD 的黑人患者更有可能在随访期间出现新脓肿(OR,2.27;95%CI,1.31-3.93)和开始使用抗肿瘤坏死因子治疗(OR,1.85;95%CI,1.09-3.14)。溃疡性结肠炎的黑人患者在基线时更有可能患有直肠炎(24%比 13%,P=0.033)。在随访期间,手术或住院率没有差异。
在本队列中,患有 CD 的黑人患者在基线和随访期间表现出更多的并发症。尽管疾病更复杂,但在研究期间,黑人患者和白人患者的 IBD 一般都给予相同的药物,并且经历相似的住院和手术率。在我们的多中心队列中,黑人患者和白人患者的 IBD 临床结局相似。